- Revvity, Inc. PKI reported the first quarter of FY23 revenues of $674.87 million, missing the consensus of $751.04 million. Revenues fell 29.9% year over year.
- Formerly known as PerkinElmer, the diagnostics and scientific solutions firm reported adjusted earnings per share of $1.01, missing the analyst consensus of $1.06.
- Weakness in diagnostics revenues and lower margins weighed on the quarterly performance.
- Segments: Lifesciences revenues rose 7.3% Y/Y to $328.44 million. Diagnostics revenues fell 47.3% to $346.63 million.
- Adjusted operating profit margin slumped a massive 1,280 basis points to 28%, as compared to 40.8% Y/Y.
- The company exited the quarter with $2.5 billion in cash and equivalents. Long-term debt stands at $3.88 billion.
- Stock Ticker Change: The company's stock ticker will change from PKI to RVTY with the beginning of trading on May 16, 2023.
- Guidance: For the full year 2023, the company forecasts total revenue of $2.90 billion -$2.94 billion versus the consensus of $2.95 billion. Earlier, the company expected revenues of $2.94 billion.
- The company sees Adjusted EPS of $4.85-$5.05, versus the consensus of $5.11. The earlier forecast was $5.05 per share.
- Price Action: PKI shares traded lower by 6.68% at $116.22 on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
